Passage Bio Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Passage Bio, Inc. (PASG) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-64.77-102.06-136.13-185.39-112.23
Depreciation & Amortization3.083.723.681.541.43
Stock Based Compensation5.8210.9218.9532.6914.58
Change in Working Capital4.205.34-8.4911.426.46
Change in Accounts Payable-0.56-2.79-5.412.204.59
Change in Other Working Capital-3.478.133.009.229.85
Other Operating Activities8.2319.953.002.0822.82
Net Cash from Operating Activities-47.96-78.26-118.21-126.88-80.52
Investing Activities
Capital Expenditures-0.03-0.15-5.27-17.641.65
Purchases of Investments-88.1765.38-157.84-20.17-170.46
Sales/Maturities of Investments143.1565.38188.31-8.00-170.46
Net Cash from Investing Activities54.9565.2425.20-45.81-172.11
Financing Activities
Common Stock Issued8.740.140.43166.99228.47
Other Financing Activities0.130.00-1.79-0.341.00
Net Cash from Financing Activities8.870.14-1.35166.66228.75
Summary
Net Change in Cash15.86-12.89-94.36-6.04-23.87
Cash at Beginning of Period21.7134.60128.97135.00158.87
Cash at End of Period37.5721.7134.60128.97135.00
Free Cash Flow-47.99-78.41-123.48-144.52-82.17